TET protein inhibitors: Potential and limitations

CSLog in Log in (EduId)

Přehled o publikaci

J 2023

TET protein inhibitors: Potential and limitations

KAPLÁNEK, Robert, Zdeněk KEJÍK, Jan HAJDUCH, Kateřina VESELÁ, Kateřina KUČNIROVÁ et. al.

Basic information

Original name

TET protein inhibitors: Potential and limitations

Authors

Edition

PHARMACOTHERAPY, Paris, ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2023, 0753-3322

Other information

Language

English

Type of outcome

Article in a journal

Country of publisher

France

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Organization

Lékařská fakulta – Repository – Repository

DOI

http://dx.doi.org/10.1016/j.biopha.2023.115324

UT WoS

001060916100001

EID Scopus

2-s2.0-85168132692

Keywords in English

TET protein; Inhibitor; Cancer; Therapy; Mitochondria

Links

LM2023053, research and development project. LX22NPO5102, research and development project. LX22NPO5107, research and development project. NU21-09-00541, research and development project. TN01000013, research and development project. TN02000109, research and development project. EATRIS-CZ IV, large research infrastructures.

Changed: 25/11/2023 03:21, RNDr. Daniel Jakubík

Abstract

V originále

TET proteins (methylcytosine dioxygenases) play an important role in the regulation of gene expression. Dysregulation of their activity is associated with many serious pathogenic states such as oncological diseases. Regulation of their activity by specific inhibitors could represent a promising therapeutic strategy. Therefore, this review describes various types of TET protein inhibitors in terms of their inhibitory mechanism and possible applicability. The potential and possible limitations of this approach are thoroughly discussed in the context of TET protein functionality in living systems. Furthermore, possible therapeutic strategies based on the inhibition of TET proteins are presented and evaluated, especially in the field of oncological diseases.

Files attached

https://is.muni.cz/publication/2305123/TET_protein_inhibitors_Potential_and_limitations.pdf

Cite

KAPLÁNEK, Robert, Zdeněk KEJÍK, Jan HAJDUCH, Kateřina VESELÁ, Kateřina KUČNIROVÁ, Markéta SKALIČKOVÁ, Anna VENHAUEROVÁ, Božena HOSNEDLOVÁ, Róbert HROMÁDKA, Petr DYTRYCH, Petr NOVOTNÝ, Nikita ABRAMENKO, Veronika ANTONYOVÁ, David HOSKOVEC, Petr BABULA, Michal MASAŘÍK, Pavel MARTÁSEK and Milan JAKUBEK. TET protein inhibitors: Potential and limitations. PHARMACOTHERAPY. Paris: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2023, vol. 166, October 2023, p. 1-15. ISSN 0753-3322. Available from: https://dx.doi.org/10.1016/j.biopha.2023.115324.

@article{57266,
   author = {Kaplánek, Robert and Kejík, Zdeněk and Hajduch, Jan and Veselá, Kateřina and Kučnirová, Kateřina and Skaličková, Markéta and Venhauerová, Anna and Hosnedlová, Božena and Hromádka, Róbert and Dytrych, Petr and Novotný, Petr and Abramenko, Nikita and Antonyová, Veronika and Hoskovec, David and Babula, Petr and Masařík, Michal and Martásek, Pavel and Jakubek, Milan},
   article_location = {Paris},
   article_number = {October 2023},
   doi = {http://dx.doi.org/10.1016/j.biopha.2023.115324},
   keywords = {TET protein; Inhibitor; Cancer; Therapy; Mitochondria},
   language = {eng},
   issn = {0753-3322},
   journal = {PHARMACOTHERAPY},
   title = {TET protein inhibitors: Potential and limitations},
   url = {https://www.sciencedirect.com/science/article/pii/S0753332223011150?via%3Dihub},
   volume = {166},
   year = {2023}
}

TY  - JOUR
ID  - 57266
AU  - Kaplánek, Robert - Kejík, Zdeněk - Hajduch, Jan - Veselá, Kateřina - Kučnirová, Kateřina - Skaličková, Markéta - Venhauerová, Anna - Hosnedlová, Božena - Hromádka, Róbert - Dytrych, Petr - Novotný, Petr - Abramenko, Nikita - Antonyová, Veronika - Hoskovec, David - Babula, Petr - Masařík, Michal - Martásek, Pavel - Jakubek, Milan
PY  - 2023
TI  - TET protein inhibitors: Potential and limitations
JF  - PHARMACOTHERAPY
VL  - 166
IS  - October 2023
SP  - 1-15
EP  - 1-15
PB  - ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
SN  - 0753-3322
KW  - TET protein
KW  - Inhibitor
KW  - Cancer
KW  - Therapy
KW  - Mitochondria
UR  - https://www.sciencedirect.com/science/article/pii/S0753332223011150?via%3Dihub
N2  - TET proteins (methylcytosine dioxygenases) play an important role in the regulation of gene expression. Dysregulation of their activity is associated with many serious pathogenic states such as oncological diseases. Regulation of their activity by specific inhibitors could represent a promising therapeutic strategy. Therefore, this review describes various types of TET protein inhibitors in terms of their inhibitory mechanism and possible applicability. The potential and possible limitations of this approach are thoroughly discussed in the context of TET protein functionality in living systems. Furthermore, possible therapeutic strategies based on the inhibition of TET proteins are presented and evaluated, especially in the field of oncological diseases.
ER  -

KAPLÁNEK, Robert, Zdeněk KEJÍK, Jan HAJDUCH, Kateřina VESELÁ, Kateřina KUČNIROVÁ, Markéta SKALIČKOVÁ, Anna VENHAUEROVÁ, Božena HOSNEDLOVÁ, Róbert HROMÁDKA, Petr DYTRYCH, Petr NOVOTNÝ, Nikita ABRAMENKO, Veronika ANTONYOVÁ, David HOSKOVEC, Petr BABULA, Michal MASAŘÍK, Pavel MARTÁSEK and Milan JAKUBEK. TET protein inhibitors: Potential and limitations. \textit{PHARMACOTHERAPY}. Paris: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2023, vol.~166, October 2023, p.~1-15. ISSN~0753-3322. Available from: https://dx.doi.org/10.1016/j.biopha.2023.115324.